ImpediMed Ltd (ImpediMed) is a manufacturer of bioimpedance devices with a focus on medical applications in the fluid status domain. The company also designs, manufactures, and sells bioimpedance spectroscopy (BIS) devices for assessing lymphoedema and body composition. It harnesses BIS technologies in the non-invasive clinical assessment and monitoring of fluid status. Its major products include SOZO, SFB7, L-Dex U400, ImpediVET, and DF50. Its products are based on BIS and bioimpedance analysis platform technologies and they obtain readings from a wide frequency range to improve the accuracy of bioimpedance analysis. The company sells its products through distributors in Australia, Europe, and the US. ImpediMed is headquartered in Brisbane, Queensland, Australia.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company ImpediMed Ltd
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company
ImpediMed Ltd Company Overview
ImpediMed Ltd Company Snapshot
ImpediMed Ltd Pipeline Products and Ongoing Clinical Trials Overview
ImpediMed Ltd – Pipeline Analysis Overview
Business Description
ImpediMed Ltd - Key Facts
ImpediMed Ltd - Major Products and Services
ImpediMed Ltd Pipeline Products by Development Stage
ImpediMed Ltd Ongoing Clinical Trials by Trial Status
ImpediMed Ltd Pipeline Products Overview
SFB 9
SFB 9 Product Overview
SOZO - Renal Failure
SOZO - Renal Failure Product Overview
SOZO - Renal Failure Clinical Trial
SOZO Pro - Lymphedema Analysis
SOZO Pro - Lymphedema Analysis Product Overview
SOZO Pro - Protein Calorie Malnutrition Analysis
SOZO Pro - Protein Calorie Malnutrition Analysis Product Overview
ImpediMed Ltd - Key Competitors
ImpediMed Ltd - Key Employees
ImpediMed Ltd - Key Employee Biographies
ImpediMed Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
ImpediMed Ltd, Recent Developments
Nov 02, 2023: ImpediMed Receives Additional 510(k) Clearance for SOZO Pro
Jul 31, 2023: Five Additional Positive Medical Policies Achieved
Jul 19, 2023: First Top 5 National Payor Covering SOZO Testing for Cancer Patients at Risk for Lymphoedema
Jun 29, 2023: Impedimed Achieves Critical Mass (80% Covered Lives) For Sozo Reimbursement Coverage in First Key Target State
Jun 20, 2023: Impedimed Announces Third Medical Policy Covering Sozo Testing for Cancer Patients at Risk for Lymphoedema
Jun 05, 2023: Impedimed Announces First Published Medical Policy From a Blue Cross Blue Shield Health Plan Covering L-DEX
May 25, 2023: Impedimed announces first published medical policy covering bioimpedance spectroscopy testing for breast cancer patients
May 05, 2023: SOZO Pro achieves clearance by U.S. FDA
Mar 27, 2023: NCCN guidelines updated to recommend regular screening for lymphoedema including with bioimpedance spectroscopy
Dec 23, 2022: ImpediMed : Update to expected release of NCCN Guidelines